Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Field & Main Bank

Field & Main Bank increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,396 shares of the medical equipment provider’s stock after acquiring an additional 24 shares during the quarter. Field & Main Bank’s holdings in Intuitive Surgical were worth $1,668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of ISRG. Creekmur Asset Management LLC lifted its position in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. Ridgewood Investments LLC acquired a new position in Intuitive Surgical in the second quarter valued at about $26,000. Delos Wealth Advisors LLC increased its stake in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares during the period. Godsey & Gibb Inc. increased its stake in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the period. Finally, LRI Investments LLC purchased a new stake in Intuitive Surgical during the first quarter worth about $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the completion of the transaction, the chief executive officer now owns 24,219 shares of the company’s stock, valued at $12,391,166.97. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Brian Edward Miller sold 2,553 shares of Intuitive Surgical stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,314,795.00. Following the transaction, the executive vice president now directly owns 7,066 shares of the company’s stock, valued at $3,638,990. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,246 shares of company stock valued at $33,839,308. 0.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wells Fargo & Company boosted their price target on shares of Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a research note on Friday, October 18th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. JPMorgan Chase & Co. boosted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Raymond James raised their target price on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Trading Up 2.3 %

Shares of ISRG opened at $536.45 on Friday. The company’s 50 day simple moving average is $493.92 and its 200-day simple moving average is $451.73. Intuitive Surgical, Inc. has a 12-month low of $269.49 and a 12-month high of $538.49. The firm has a market cap of $191.07 billion, a PE ratio of 86.25, a price-to-earnings-growth ratio of 5.07 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.